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Abstract
Aims/hypothesis. The ACE inhibitor cilazapril was ad-
ministered to diabetic hypertensive rats to evaluate its
ability to influence the development of retinal capil-
lary alterations.
Methods. Normotensive (strain: Wistar Kyoto) and ge-
netically hypertensive (strain: spontaneously hyper-
tensive) rats were rendered diabetic by intravenous in-
jections of streptozotocin. Half of the diabetic animals
received cilazapril with their daily food. At 20 weeks
of diabetes, endothelial cells, pericytes and extracellu-
lar matrix were assessed by ultrastructural morphome-
try. Each experimental group consisted of seven ani-
mals.
Results. Cilazapril normalised systolic arterial pres-
sure in diabetic hypertensive rats (137±2 mm Hg com-
pared with 188±16 mm Hg in non-medicated diabetic
hypertensive rats, p<0.001). The number of endo-
thelial intercellular junctions was reduced in untreated
diabetic hypertensive rats (0.15±0.05, p<0.02, vs
0.47±0.20 in non-diabetic normotensive rats). In dia-
betic hypertensive animals treated with cilazapril, this
loss was attenuated (0.32±0.16, p<0.05). The signifi-
cant thickening of the basement membrane observed
in the diabetic normotensive (132.8±19.4 nm) and 
diabetic hypertensive (150.3±20.2 nm) groups was 
decreased by cilazapril in the diabetic hypertensive
group (116.7±11.0 nm, p<0.01), but was unaffected in
the normotensive (131.9±17.3 nm) group. No protec-
tive effect of the drug was observed in either group on
pericytes.
Conclusions/interpretation. Long-term administration
of an effective antihypertensive therapy normalises
endothelial alterations and basement membrane thick-
ness in diabetic hypertensive conditions, and thus may
account for the well-known improvement of the
blood-retinal barrier observed during antihypertensive
treatment.
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Introduction
Most diabetic patients will develop diabetic retinopa-
thy [1, 2, 3] and, despite the beneficial effect of photo-
coagulation, diabetic retinopathy remains the leading
cause of blindness in young adults [4, 5]. Duration of
diabetes [6, 7, 8], poor blood glucose control [9], and
systemic hypertension [10, 11, 12, 13, 14, 15] are es-
tablished risk factors for the development of retinopa-
thy and its further progression.
There is little doubt that strict glucose control is es-
sential in the management of diabetic retinopathy.
However, another important and, probably decisive in-
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tervention is to normalise blood pressure [16, 17, 18].
Currently, the combination of strict metabolic and
blood pressure control is the most promising preven-
tive strategy and should be provided to all diabetic 
patients.
The mechanisms by which an antihypertensive
treatment protects the retina are largely unknown.
There is evidence that hypertension induces shear
stress, leading, in an initial phase, to hyperplasia of
the vascular endothelium and to hypertrophia of its
cytoskeleton [19], and later to degenerative processes
[20], followed ultimately by the formation of acellular
capillaries [19, 20]. Lowering blood pressure might
decrease the shear stress exerted on the vascular wall.
However, it has also been claimed that the beneficial
action of an antihypertensive drug is not restricted to
its hypotensive effect [21, 22, 23]. Indeed, a potential
role for the renin-angiotensin system (RAS) in the 
development of retinopathy has been suggested by 
the finding that diabetic retinopathy is associated with
elevated levels of plasma prorenin and ACE, and with
an enhanced prorenin and renin content in the vitreous
fluid [24, 25]. Moreover, renin and ACE, two key 
enzymes of the metabolic pathway of angiotensin II
(ANGII) synthesis, have been localised at the level 
of the retinal vasculature [26, 27]. Thus, it is likely
that direct inhibition of retinal ACE accounts for the
beneficial effect of this kind of systemic antihyperten-
sive treatment on the development of retinopathy [22,
28].
Here, we present morphometric data on the effect
of the ACE inhibitor cilazapril on the ultrastructure of
the capillary wall in the rat retina of the normotensive
Wistar Kyoto (WKY) and the spontaneously hyperten-
sive (SHR) strain, both rendered diabetic by streptozo-
tocin (STZ). This study is an extension of previously
published data from our laboratory, demonstrating im-
portant remodelling of the capillary wall in retinas of
non-treated diabetic and hypertensive animals [29].
We present these data for comparison, since the exper-
iments were done concurrently on age-matched sib-
lings.
Materials and methods
Animals and anaesthesia. All animal care and handling were
conducted in accordance with the ARVO Statement for the Use
of Animals in Ophthalmic and Vision Research, and with the
Swiss Law on Animal Protection.
Spontaneously hypertensive male SHR rats and their nor-
motensive WKY counterparts were purchased from Iffa Credo,
Lyon, France. At 7 weeks of age (mean weight 240 g), they
were rendered diabetic by a single intravenous injection of
streptozotocin (60 mg/kg body weight; Sigma, Buchs, Switzer-
land). All animals were kept under identical light conditions on
a 14-h light ON and 10-h light OFF cycle and given free ac-
cess to a normal diet and water, except that half of the diabetic
rats of both strains received cilazapril (10 mg/kg body weight)
with their daily food for the duration of the experiment. Non-
diabetic and untreated SHR and WKY littermates served as
controls.
Body weight, glucose levels after an overnight fast, as well
as basal glucose levels were determined with a glucose ana-
lyser (Beckman Instruments, Zurich, Switzerland) at monthly
intervals. Systolic blood pressure was measured monthly in the
conscious state, by indirect tail cuff plethysmography. It was
also measured immediately before the animals were killed at
the end of the study, 20 weeks after induction of diabetes.
Anaesthesia was induced with 2% isoflurane given into an
air stream and maintained with an intraperitoneal injection of
pentothal (Abbott, Cham, Switzerland). The animals were
killed by intracardiac injection of 1 mol/l KCl before enucle-
ation.
Tissue processing and morphometric measurements. The mor-
phometric study comprised five experimental groups of seven
animals each: SHR-D (hypertensive diabetic), SHR-Dt (hyper-
tensive diabetic treated with cilazapril), WKY-N (normoten-
sive non-diabetic), WKY-D (normotensive diabetic), WKY-Dt
(normotensive diabetic treated with cilazapril).
Tissue processing, electron microscopy, morphometric
measurements and statistics were performed as detailed in a
previous study [29]. Briefly, enucleated eyes were immersion-
fixed in 2.5% glutaraldehyde in 0.1 mol/l cacodylate buffer
(pH 7.4) containing 0.2% tannic acid, washed in the same 
buffer, and post-fixed in 0.5% osmium tetroxide. Tissue pieces
were block-stained with uranyl acetate, dehydrated through a
graded series of ethanol, and embedded in Epon.
Computer-assisted morphometric measurements were done
on electron micrographs taken from ten to twelve randomly se-
lected capillaries of the outer plexiform layer from four differ-
ent tissue blocks of the same retina. Only cross-sectioned cap-
illaries were considered. Thus, a total of up to 84 capillaries
per experimental group were evaluated. To assess the caliber
of the capillaries, the thickness of the basement membrane, as
well as the size and shape of endothelial cells and pericytes,
eight different measurements were performed (details, see
[29]).
Statistical analysis. The parameters are given as the mean ± SD.
The significance of differences between groups was tested by
ANOVA and the Student-Newman-Keuls test [30]. A p value of
0.05 was considered statistically significant. All measurements
were carried out in a masked manner without prior knowledge
of the capillary’s origin.
Results
Weight, blood glucose and arterial pressure
The metabolic and physical parameters are shown in Ta-
ble 1. The mean systolic blood pressure was significant-
ly higher in the diabetic SHR strain (188±16 mm Hg)
than in the diabetic WKY strain (145±8 mm Hg). In the
SHR group treated with cilazapril, systolic blood pres-
sure was lowered to the normal values seen in the
WKY-N group (135±13 mm Hg). However, this anti-
hypertensive treatment had no effect on blood glucose 
levels in the diabetic animals of either strain (WKY-D,
38.0±3.1 mmol/l; WKY-Dt, 37.1±1.8 mmol/l; SHR-D,
40.7±3.3 mmol/l; SHR-Dt, 39.8±1.0 mmol/l).
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Morphometric measurements of retinal capillaries
Capillary caliber. Comparing the inner and outer
basement area, we noted elevated values specifi-
cally in the normotensive diabetic (WKY-D) group
(41.2±3.0 µm2 and 55.9±5.4 µm2 respectively), sug-
gesting a tendency of these vessels to dilate (Table 2).
By contrast, all other groups had more and less the
same values as the normotensive non-diabetic rats
(36.5±5.2 µm2 and 50.2±8.3 µm2 respectively).
Basement membrane. The most striking alteration in
the diabetic animals, readily detectable by electron
microscopy, was a pronounced thickening of the base-
ment membrane. Figure 1 shows a cross-section
through a retinal capillary of a hypertensive diabetic
(SHR-D) rat with a focally thickened extracellular
matrix in regions where the endothelial cell is in con-
tact with a Müller glial cell process.
Compared with the normotensive non-diabetic con-
trols (WKY-N, 111.8±14.2 nm), both the normotensive
(WKY-D, 132.8±19.4 nm, p<0.05) and the hyper-
tensive diabetic (SHR-D, 150.3±20.2 nm, p<0.005)
groups (Table 2) showed a significant increase in
thickness in these regions of the basement membrane.
This value was fully normalised in the cilazapril-treat-
ed hypertensive diabetic rats (SHR-Dt, 116.7±11.0 nm,
p<0.01). Cilazapril did not, however, normalise base-
ment membrane thickness in the normotensive diabetic
(WKY-Dt, 131.9±17.3 nm) rats.
Endothelial cells. Counts of the number of nuclear
cross-sections did not reveal any loss of endothelial
cells in any of the experimental groups. Compared
with the controls (WKY-N, 15.6±2.4 µm2), a signifi-
cant decrease of the cytoplasmic area of endothelial
cells was noted in the normotensive diabetic (WKY-D,
11.5±3.0 µm2, p<0.02) and the cilazapril-treated dia-
Table 1. Metabolic and physical parameters of normotensive non-diabetic (WKY-N), normotensive diabetic (WKY-D), treated nor-
motensive diabetic (WKY-Dt). hypertensive diabetic (SHR-D) and treated hypertensive diabetic(SHR-Dt) rats at 27 weeks of age
WKY-N WKY-D WKY-Dt SHR-D SHR-Dt p values
Basal blood glucose (mmol/l) 7.0±1.2 38.0±3.1 37.1±1.8 40.7±3.3 39.8±1.0 0.001a,b,c,d
Fasting blood glucose (mmol/l) 5.1±0.4 18.9±4.3 15.1±1.6 20±4.5 17.9±4.2 0.001a,b,c,d
Body weight (g) 429±21 165±11 160±22 175±15 190±28 0.001a,b,c,d
Systolic blood pressure (mm Hg) 135±13 145±8 132±9 188±16 137±2 0.001c,e,f,g
Values (for seven rats per group) are given as means ± SD. 
a WKY-N compared with WKY-D; b WKY-N compared with
WKY-Dt; c WKY-N compared with SHR-D; d WKY-N com-
pared with SHR-Dt; e SHR-D compared with SHR-Dt; f SHR-D
compared with WKY-Dt; g SHR-D compared with WKY-D
Table 2. Ultrastructural morphometry of capillaries of the retina in normotensive non-diabetic (WKY-N), normotensive diabetic
(WKY-D), treated normotensive diabetic (WKY-Dt), hypertensive diabetic (SHR-D) and treated hypertensive diabetic (SHR-Dt) rats
WKY-N WKY-D WKY-Dt SHR-D SHR-Dt p values
Caliber of retinal capillaries
Inner basement membrane area (µm2) 36.5±5.2 41.2±3.0 35±2.5 35.4±3.3 34.7±5.4
Outer basement membrane area (µm2) 50.2±8.3 55.9±5.4 49.9±6.0 50.7±5.1 48.2±6.6
Basement membrane
Thickness (nm) 111.8±14.2 132.8±19.4 131.9±17.3 150.3±20.2 116.7±11.0 <0.05a, <0.05b,
<0.005c, <0.01e
Endothelial cells
Endothelial cytoplasmic area (µm2) 15.6±2.4 11.5±3.0 10.1±2.2 13.0±3.5 10.9±4.2 <0.02a, <0.01b,
<0.02d
Lumen area (µm2) 9.5±4.8 16.1±1.7 12.7±2.3 13.1±3.0 10.8±3.7 <0.05a
Endothelial pseudopod pair per capillary 0.47±0.20 0.30±0.13 0.27±0.06 0.15±0.05 0.32±0.16 <0.02c, <0.05e
Endothelial nuclei per capillary 0.78±0.12 0.79±0.20 0.68±0.14 0.69±0.23 0.66±0.25
Pericytes
IBML covered by pericytes (%) 35.8±12.0 19.4±1.3 21.9±2.7 21.4±4.5 21.5±2.1 <0.001a, <0.05b,
<0.003c, <0.002d
Pericyte processes per capillary 2.3±0.7 1.7±0.2 2.0±0.3 1.9±0.3 1.7±1.0 <0.02a
Pericyte nuclei per capillary 0.37±0.10 0.24±0.06 0.22±0.07 0.18±0.12 0.23±0.10 <0.04a, <0.02b,
<0.02c
Values are for seven animals per group. a WKY-N compared
with WKY-D; b WKY-N compared with WKY-Dt; c WKY-N
compared with SHR-D; d WKY-N compared with SHR-Dt; 
e SHR-D compared with SHR-Dt. All comparisons were statis-
tically considered, but only the significant p values are indi-
cated. IBML, inner basement membrane length
cantly smaller in the diabetic groups of both strains
(WKY-N, 0.37±0.10; WKY-D, 0.24±0.06, p<0.04;
SHR-D, 0.18±0.12, p<0.02). This loss was not cor-
rected by cilazapril. The treatment did not influence
covering of the endothelial cell by pericyte processes,
nor did it influence the number of pericyte processes,
indicating that the pericyte shape was not improved.
Discussion
We found that treatment with the ACE inhibitor
cilazapril significantly improved morphological fea-
tures in retinal capillaries of the hypertensive diabetic
rat. Cilazapril normalised the thickness of the base-
ment membrane and the shape of the endothelial cells.
However, a complete normalisation was not achieved.
Neither did we observe any change in the morphology
of the pericytes.
By lowering systemic blood pressure, ACE in-
hibitors reduce shear stress exerted on the endothelial
wall. This makes the endothelial cell the primary tar-
get of the treatment, leaving the pericyte virtually un-
affected. Indeed, this cellular preference was observed
in our study. However, it is likely that the beneficial
effect of ACE inhibitors in the retina goes well be-
yond a general haemodynamic action and intervenes
in pathways that specifically relate to signalling of the
local RAS controlling autoregulation of the retinal cir-
culation [27]. Indeed, all components of the RAS have
been localised in retinal vessels [31, 32, 33, 34, 35],
and both impaired RAS [22, 36, 37] and deficient vas-
cular autoregulation [38] have been associated with
diabetic retinopathy. In the hypertensive retina, failure
in autoregulation may directly transmit elevated sys-
temic blood pressure down to the microcirculation,
causing capillary hypertension and eventually struc-
tural damage to the endothelial cells. Thus, improve-
ment of retinal autoregulation by ACE inhibitors may
contribute to the formation of a haemodynamic milieu
capable even of attenuating the progression of diabetic
retinopathy [38].
It is possible that ACE inhibitors have other protec-
tive functions. For instance, by inhibiting bradykinin
degradation, ACE inhibitors promote an increase in
nitric oxide and prostacyclin [39]. It has been shown
that, through this mechanism, Na,K-ATPase in the 
retinal vasculature is increased [40] and its activity in
the diabetic retina improved [22]. Yet, it remains to be
seen whether the functional improvement detected by
electroretinography [41] can be directly related to the
action of ACE inhibitors on the Na,K-ATPase system.
It is also not known to what extent the pathway via
Na,K-ATPase has an impact on the morphological fea-
tures considered in this study.
Most importantly, RAS is also involved in growth
factor expression, in particular of vascular endothelial
growth factor (VEGF) and TGF-beta. Indeed, in-
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betic groups of both strains (WKY-Dt, 10.1±2.2 µm2,
p<0.01; SHR-Dt, 10.9±4.2 µm2, p<0.02). Moreover, in
the WKY-D group, the vascular lumen area was sig-
nificantly enlarged (16.1±1.7 µm2 vs 9.5±4.8 µm2 in
WKY-N, p<0.05), reflecting a marked thinning of the
endothelial layer in diabetic animals. A similar,
though not significant tendency was observed in the
SHR-D group (13.1±3.0 µm2). In both cilazapril-treat-
ed diabetic groups, however, a tendency to normalise
the lumen area was noted (WKY-Dt, 12.7±2.3 µm2;
SHR-Dt, 10.8±3.7 µm2).
To estimate the number of intercellular junctions (see
Fig. 1), the number of cytoplasmic pseudopod pairs that
are regularly associated with intercellular junctions was
determined (Table 2). Compared with normotensive
non-diabetic animals (WKY-N, 0.47±0.20), we found 
a significant reduction in the hypertensive diabetic
SHR-D group (0.15±0.05, p<0.02), reflecting a less 
intricate shape of the endothelial cells. Cilazapril treat-
ment restored the number of pseudopod pairs in the
SHR-Dt (0.32±0.16, p<0.05) but not in the WKY-Dt
group (0.27±0.06).
Pericytes. In contrast to the endothelial cells, the num-
ber of nuclear cross-sections of pericytes was signifi-
Fig. 1. Electron micrograph of a capillary from the outer plexi-
form layer of a spontaneously hypertensive, diabetic rat. EN, en-
dothelial cell nucleus; EP, endothelial pseudopod pairs associat-
ed with intercellular junction; G, glia limitans; I, intercellular
junction; L, vessel lumen; PN, pericyte nucleus; PP, pericyte pro-
cess. The arrowhead denotes the segment of the outer basement
membrane, between endothelial cell and glia limitans, that was
used to measure basement membrane width. The arrow points to
focal thickenings of the basement membrane. Scale bar: 1 µm
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creased VEGF expression in the diabetic rat [42] can
be normalised by ACE inhibition [43, 44]. Moreover,
TGF-beta signalling contributes substantially to the
turnover of the extracellular matrix [45]. In the pres-
ence of high glucose, angiotensin II has been shown to
stimulate secretion of TGF-beta [46] and to increase
matrix accumulation [47] by activating the synthesis
of collagen I [48] and fibronectin [49] and by decreas-
ing matrix degradation [50]. Thus, the blockage of an-
giotensin II formation by ACE inhibitors decreases
the expression of TGF-beta, reduces the accumulation
of matrix protein synthesis [51], and accelerates its
degradation [52, 53]. In line with these observations,
the significant reduction in the thickness of retinal
capillary basement lamina that we observed after
treatment with captopril may be mediated by TGF-
beta. Indeed, in an ongoing study we are now testing
the extent to which TGF-beta is engaged in the patho-
genesis of retinopathy.
The selectivity of the endothelial cell as a target of
ACE inhibitors noted in vivo in this study and in [54]
and in vitro [41, 54] may explain why excessive leak-
age of the blood-retinal barrier in patients [21, 23] and
diabetic animals [43] was prevented by long-term treat-
ment. Yet, it remains to be seen why no improvement
of the capillary parameters considered in our experi-
ments were found in the normotensive diabetic group.
It is likely that the threshold levels of the numerous
triggers, as well as the complexity and activity of the
various signalling pathways involved, differ in the hy-
perglycaemic, the hypertensive, and the combined con-
dition. These differences may result, at least in part, in
different levels of responsiveness to a particular drug.
In conclusion, our observations show that the long-
term administration of cilazapril not only decreases
systolic arterial pressure to near normal levels, but
also prevents basement membrane thickening and 
alterations of the endothelial cell in the hypertensive
diabetic animal. Whether this benefit is achieved 
exclusively through the lowering of blood pressure 
or by other mechanisms remains to be clarified. In 
accordance with clinical studies [16, 17, 18], our ob-
servations support recommendations that systemic
blood pressure be strictly controlled.
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